Stock AVTE AEROVATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
21.75 USD +0.83% Intraday chart for Aerovate Therapeutics, Inc. -1.36% -3.89%
04-12 Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing MT
04-04 Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing
Aerovate Therapeutics Q4 Loss Widens
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing
Aerovate Therapeutics, Inc. Announces Board Changes
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors
Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Aerovate Therapeutics, Inc. Announces Progress on IMPAHCT Global Phase 2b/Phase 3 Clinical Trial of AV-101 for Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. Appoints Donald Santel To Its Board of Directors
Top Midday Gainers
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Insider Sell: Aerovate Therapeutics
Aerovate Therapeutics Reports Wider Q3 Net Loss
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVTE Stock
  4. News Aerovate Therapeutics, Inc.
  5. Other languages